Participación contratos de I+D

GINDe participa o ha participado en los siguientes contratos de investigación con diferentes empresas:

A phase 4, open-label, multicentre, 2-year safety study of lisdexamfetamine dimesylate in children and adolescents aged 6-17 years with attention-deficit/hyperactivity disorder (ADHD).

  • Empresa/Administración financiadora: Shire Development Inc.
  • Duración: 2011-2014.
  • Investigador responsable: Belén Rubio.
  • Estudio europeo – multicentro

A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.

  • Empresa/Administración financiadora: Shire Development Inc.
  • Duración: 2010-2011
  • Investigadora responsable: Belén Rubio.
  • Estudio europeo – multicentro

A phase III, open-label, extension, multicentre, safety study of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).

  • Empresa/Administración financiadora: Shire Development Inc.
  • Duración: 2009 – 2010
  • Investigadora Responsable: Belén Rubio.

Evaluación Neuropsicológica de la Eficacia de la Atomoxetina en el Trastorno por Déficit de Atención con Hiperactividad (TDAH)

  • Empresa/Administración financiadora: Laboratorio Lilly S. A.
  • Duración: 2009-2011
  • Investigador responsable: Sergio Hernández Expósito

A phase III, randomised, double-blind, multicentre, parallel-group, placeboand active-controlled, dose-optimisation safety and efficacy study of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).

  • Empresa/Administración financiadora: Shire Development Inc
  • Duración: 2008  – 2009
  • Investigadora Responsable: Belén Rubio Morell.